SEC Tracker
Get the app

Palvella Therapeutics PVLA

Palvella Therapeutics announces Q3 2026 financial results

Item 2.02 Reports results, Item 7.01 Investor disclosure

Form
8-K
Filed
Importance
Major
  1. FDA accepts NDA for QTORIN™ rapamycin with PDUFA target action date of February 28, 2027
  2. Cash, cash equivalents, and short-term investments of $236.7 million as of September 30, 2026
  3. Plans to announce fourth target clinical indication for QTORIN™ rapamycin in Q4 2026

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Palvella Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Esperion Therapeutics ESPR public float $198M, Jun 30, 2025
  2. Editas Medicine EDIT public float $191M, Jun 30, 2025
  3. Rezolute RZLT public float $204M, Dec 31, 2025
  4. Cardiff Oncology CRDF public float $205M, Jun 30, 2025
  5. Silence Therapeutics SLN public float $206M, Jun 30, 2025